Could a common liver drug help beat severe COVID-19?
NCT ID NCT04374461
First seen Jan 02, 2026 · Last updated May 07, 2026 · Updated 19 times
Summary
This study tests whether N-acetylcysteine, a drug already used for liver protection and lung mucus thinning, can help people with severe COVID-19. The idea is that it may boost the immune system to fight the virus better. About 48 very ill adults in the hospital or on a ventilator will receive the drug to see if they can leave intensive care or be taken off a ventilator sooner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.